NASDAQ
MTRI
Last Price
US $18.6
KEY FIGURES
MKT CAP
$10.2M
EPS
TTM$-22.69
EPS Growth (1Y)
-62.68%
PEG
TTMN/M
P/E
TTMN/M
P/S
TTM-
YIELD
—
GROWTH (5Y CAGR)
Revenue
-
EBITDA
-
Cash flow
Valuation
Financial
Performance
Cash flow to debt coverage
Mentari Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.
Free cash flow growth
Mentari Therapeutics, Inc.'s free cash flow has decreased 11.29% from $-7.77M last year to $-8.64M, signaling decreasing performance
Debt-to-equity ratio
Mentari Therapeutics, Inc. has insufficient data to evaluate this check.
Debt-to-equity trend
Mentari Therapeutics, Inc. has insufficient data to evaluate this check.
Net debt to EBITDA
Mentari Therapeutics, Inc. has a net cash position, so leverage is healthy.
Interest coverage
Mentari Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
Mentari Therapeutics, Inc.'s profit margin was -165.14% last year and is -0.60% this year, signaling increasing performance
Current ratio
Mentari Therapeutics, Inc. has insufficient data to evaluate this check.
Return on assets
Mentari Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Mentari Therapeutics, Inc.'s return on equity of -303.50%, is lower than 15.00%, indicating bad performance
Earnings quality
Mentari Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Earnings stability
Mentari Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings
Positive free cash flow
Mentari Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Mentari Therapeutics, Inc. has negative free cash flow, indicating cash burn
Earnings growth
Mentari Therapeutics, Inc.'s yearly earnings has decreased 53.89% since last year from $-8.16M to $-12.56M, signaling decreasing performance
Revenue growth
Mentari Therapeutics, Inc. has insufficient data to evaluate this check.
Return on invested capital
ROIC 847.04% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
3-year revenue CAGR
Mentari Therapeutics, Inc.'s 3-year revenue CAGR of 815.81% is positive, indicating growing revenue over the past 3 years
Revenue consistency
Mentari Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance
Return on equity consistency
Mentari Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity
Base Cash Flow Valuation (DCF)
Mentari Therapeutics, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Mentari Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Base EBITDA Valuation
Mentari Therapeutics, Inc. has insufficient data to evaluate this check.
EV/EBITDA (FY)
Mentari Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Mentari Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Price-to-book ratio (FY)
Mentari Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Mentari Therapeutics, Inc. has a price-to-sales ratio of 0.00x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-72.10%
Return on equity
ROIC: -59.40%
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $18.6
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.